

# CITATION REPORT

List of articles citing

## Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

DOI: 10.1161/circulationaha.118.037184  
Circulation, 2019, 139, 1483-1492.

**Source:** <https://exaly.com/paper-pdf/74780592/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
424	Strategies to Overcome Residual Risk During Statins Era. <b>2019</b> , 83, 1973-1979		14
423	Use of Inflammatory Biomarkers to Predict the Clinical Benefit of Ezetimibe: A Clinical Perspective. <b>2019</b> , 74, 1069-1070		
422	apoB/apoA-I Ratio and Lp(a) Associations With Aortic Valve Stenosis Incidence: Insights From the EPIC-Norfolk Prospective Population Study. <b>2019</b> , 8, e013020		7
421	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. <b>2019</b> , 394, 697-708		43
420	Lp(a): Addressing a Target for Cardiovascular Disease Prevention. <b>2019</b> , 21, 102		10
419	Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. <b>2019</b> , 21, 110		11
418	PCSK9 inhibition and inflammation: A narrative review. <b>2019</b> , 288, 146-155		52
417	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. <b>2019</b> , 31, 128-139		
416	Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors. <b>2019</b> , 26, 199-207		9
415	Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: An optical coherence tomography study. <b>2019</b> , 24, 100382		7
414	Low LDL Cholesterol by PCSK9 Variation Reduces Cardiovascular Mortality. <b>2019</b> , 73, 3102-3114		13
413	Therapeutic lowering of lipoprotein(a): How much is enough?. <b>2019</b> , 288, 163-165		7
412	Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. <b>2019</b> , 381, 1557-1567		102
411	HEART UK consensus statement on Lipoprotein(a): A call to action. <b>2019</b> , 291, 62-70		56
410	A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients. <b>2019</b> , 13, 1		
409	Catering to Your Concerns. <b>2019</b> , 3, 1-21		1
408	Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. <b>2019</b> , 4, 1287-1295		121

407	Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. <b>2019</b> , 33, 739-748	14
406	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <b>2019</b> , 290, 140-205	259
405	Gender Specificity and Interpretation of Functional Cardiac Imaging: Let's Talk about Sex. <b>2019</b> , 119, 1379-1381	1
404	PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults. <b>2019</b> , 60, 1946-1952	7
403	Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. <b>2019</b> , 13, 894-900	22
402	Cholesterol-Lowering Agents. <b>2019</b> , 124, 364-385	25
401	Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. <b>2019</b> , 16, 305-318	85
400	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. <b>2019</b> , 31, 128-139	13
399	LDL-C Targets in Secondary Prevention: How Low Should We Go?. <b>2019</b> , 13, 1	4
398	Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: An Emerging Role for Evolocumab?. <b>2019</b> , 73, 2971-2975	4
397	Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. <b>2019</b> , 13, 580-585	10
396	ApoB. <b>2019</b> , 124, 1425-1427	16
395	What's new on therapies for elevated lipoprotein(a). <b>2019</b> , 12, 495-499	
394	Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. <b>2019</b> , 4, 575-579	77
393	Screening for High Lipoprotein(a). <i>Circulation</i> , <b>2019</b> , 139, 1493-1496	16.7 15
392	Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. <b>2019</b> , 14, 45-50	12
391	Lipoprotein(a)-antisense therapy. <b>2019</b> , 14, 51-56	11
390	Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. <b>2019</b> , 21, 16	9

389	Lipoprotein(a). <b>2019</b> , 14, 1-4	1
388	Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?. <b>2019</b> , 30, 428-437	4
387	Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology. <b>2019</b> , 34, 519-525	2
386	Current and future role of lipoprotein(a) in preventive cardiology. <b>2019</b> , 34, 514-518	5
385	Proprotein convertase subtilisin/kexin type 9 and lipid metabolism. <b>2019</b> , 30, 186-191	7
384	Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?. <b>2019</b> , 8,	9
383	Statin therapy increases lipoprotein(a) levels. <b>2020</b> , 41, 2275-2284	134
382	The PCSK9 revolution: Current status, controversies, and future directions. <b>2020</b> , 30, 179-185	32
381	Dyslipidemia Management in Adults With Diabetes. <b>2020</b> , 44, 53-60	19
380	Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. <b>2020</b> , 40, 255-266	68
379	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <b>2020</b> , 41, 111-188	2236
378	Lipoprotein(a) Change After Sleeve Gastrectomy Is Affected by the Presence of Metabolic Syndrome. <b>2020</b> , 30, 545-552	0
377	PCSK9 inhibitors: Ratification of the role of LDL cholesterol in cardiovascular prevention. Towards a convergence of European and North American prevention guidelines?. <b>2020</b> , 220, 374-382	
376	Lipoprotein(a) plasma levels are not associated with survival after acute coronary syndromes: An observational cohort study. <b>2020</b> , 15, e0227054	8
375	Alirocumab in Polyvascular Atherosclerotic Disease. <b>2020</b> , 75, 240-241	1
374	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <b>2020</b> , 75, 133-144	147
373	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. <b>2020</b> , 75, 238-240	2
372	Lp(a)'s Odyssey: Should We Measure Lp(a) Post-ACS and What Should We Do With the Results?. <b>2020</b> , 75, 145-147	2

371	Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease. <b>2020</b> , 80, 229-239	10
370	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. <b>2020</b> , 382, 244-255	265
369	Pathophysiology of Aortic Stenosis and Future Perspectives for Medical Therapy. <b>2020</b> , 38, 1-12	14
368	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. <b>2020</b> , 58, 496-517	50
367	The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. <b>2020</b> , 43, e22-e24	8
366	Lipoprotein(a) Testing and Emerging Therapies. <b>2020</b> , 28, 250-255	1
365	Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. <b>2020</b> , 287, 2-18	44
364	Current Concepts in Management of Lipid Abnormalities in Patients With Coronary Artery Disease. <b>2020</b> , 1, 164-173	
363	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <b>2020</b> , 41, 4245-4255	44
362	Secondary prevention after CABG: do new agents change the paradigm?. <b>2020</b> , 35, 664-672	1
361	Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level. <b>2020</b> , 7,	4
360	The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives. <b>2020</b> , 61, 398-403	2
359	Coronary atherosclerotic plaque progression: contributing factors in statin-treated patients. <b>2020</b> , 18, 873-880	1
358	Lipoprotein(a) and PCSK9 inhibition: clinical evidence. <b>2020</b> , 22, L53-L56	8
357	Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events. <b>2020</b> , 9, e016318	15
356	Inflammation and cardiovascular disease: From mechanisms to therapeutics. <b>2020</b> , 4, 100130	35
355	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. <b>2020</b> , 26, 1196-1224	27
354	Inhibiteurs PCSK9'en pratique clinique': donnes et interrogations. <b>2020</b> , 14, 524-528	

353	Family History and Lipoprotein(a) Contribute Independently to Risk Assessment and Clinical Management. <b>2020</b> , 76, 794-796	1
352	Lipid Transfer in Lipoprotein Metabolism and Cardiovascular Disease. <b>2020</b> ,	1
351	Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?. <b>2020</b> , 12,	11
350	Activation of estrogen receptor $\alpha$ (ER $\alpha$ ) is required for Alisil B23-acetate to prevent post-menopausal atherosclerosis and reduced lipid accumulation. <b>2020</b> , 258, 118030	5
349	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. <b>2020</b> , 159, 4-33	23
348	Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population. <b>2020</b> , 5, 270-278	5
347	Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations. <b>2020</b> , 9, e018189	2
346	Letter by Qi et al Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism". <i>Circulation</i> , <b>2020</b> , 142, e262-e263	16.7 0
345	Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. <b>2020</b> , 16, 403-418	1
344	Quantifying apolipoprotein(a) in the era of proteoforms and precision medicine. <b>2020</b> , 511, 260-268	5
343	Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease. <b>2020</b> , 37, 4568-4584	4
342	[Lipid management 2020 - medical therapy and lipid apheresis in context]. <b>2020</b> , 145, 464-469	
341	Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia. <b>2020</b> , 22, 68	4
340	Recent advances and emerging therapies in management of dyslipidemias. <b>2021</b> , 31, 419-424	1
339	Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry. <b>2020</b> , 43, 1209-1215	1
338	Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. <b>2021</b> , 121, 1161-1168	1
337	Tackling cardiometabolic risk in the Asia Pacific region. <b>2020</b> , 4, 100096	2
336	PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects. <b>2020</b> , 11, 595819	10

335	Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis. <b>2020</b> , 21,	8
334	Preventing Aortic Stenosis by Changing the Way We Think About an Old Disease. <b>2020</b> , 5, 627-629	3
333	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. <b>2020</b> , 5, 709-713	25
332	Gene-based therapy in lipid management: the winding road from promise to practice. <b>2020</b> , 29, 483-493	9
331	Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. <b>2020</b> , 106, 1228-1235	11
330	Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a). <b>2020</b> , 19, 91	3
329	Lipid lowering therapy in cardiovascular disease: From myth to molecular reality. <b>2020</b> , 213, 107592	20
328	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. <b>2020</b> , 7, 88	29
327	Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. <b>2020</b> , 16, 361-379	36
326	Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options. <b>2020</b> , 52, 162-177	13
325	Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry. <b>2020</b> , 19, 114	2
324	Metabolism of lipoprotein(a): new findings, implications and outstanding issues. <b>2020</b> , 31, 163-165	3
323	PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy. <b>2020</b> , 75, 410-420	8
322	Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. <b>2020</b> , 135, 82-88	17
321	The dedicated "Lp(a) clinic": A concept whose time has arrived?. <b>2020</b> , 300, 1-9	24
320	Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. <b>2020</b> , 9, e014129	15
319	Coronary Artery Disease. <b>2020</b> , 40, e185-e192	7
318	Lipoprotein(a): An Enigmatic Sheep in the Lipoprotein Herd. <b>2020</b> , 5, 558-560	1

317	Genetic and In Vitro Inhibition of and Calcific Aortic Valve Stenosis. <b>2020</b> , 5, 649-661	18
316	Lipid management for cardiovascular risk reduction in type 1 diabetes. <b>2020</b> , 27, 207-214	6
315	Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach. <b>2020</b> , 9,	10
314	Further advices on measuring lipoprotein(a) for reducing the residual cardiovascular risk on statin therapy. <b>2020</b> , 58, e144-e147	1
313	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. <b>2020</b> , 17, 360-377	41
312	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. <b>2020</b> , 294, 46-61	49
311	Serum lipoprotein(a) and risk of mortality in patients on peritoneal dialysis. <b>2020</b> , 14, 252-259	3
310	A Narrative Review and Expert Panel Recommendations on Dyslipidaemia Management After Acute Coronary Syndrome in Countries Outside Western Europe and North America. <b>2020</b> , 37, 1754-1777	
309	Lipoprotein(a), the rediscovered risk factor, or how to get "back to the future". <b>2020</b> , 113, 147-151	0
308	Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. <b>2020</b> , 126, 94-102	8
307	What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?. <b>2020</b> , 63, 219-227	15
306	Antisense oligonucleotides for atherosclerotic disease. <b>2020</b> , 26, 471-472	3
305	Lipoprotein(a) and Cardiovascular Diseases - Revisited. <b>2020</b> , 84, 867-874	9
304	Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. <b>2020</b> , 34, 107593	2
303	Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. <b>2020</b> , 2047487320915803	11
302	Lipoprotein(a): Expanding our knowledge of aortic valve narrowing. <b>2021</b> , 31, 305-311	5
301	Association of lipoprotein (a) and in-hospital outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <b>2021</b> , 133, 195-201	2
300	Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study. <b>2021</b> , 26, 51-58	3



299	Lipoprotein(a) in Patients With Type 2 Diabetes and Premature Coronary Artery Disease in the Coronary Care Unit. <b>2021</b> , 30, 734-740	2
298	Lipoprotein(a) and Cardiovascular Disease. <b>2021</b> , 67, 154-166	23
297	New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. <b>2021</b> , 72, 431-446	5
296	Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. <b>2021</b> , 67, 143-153	23
295	Advances in biological therapies for dyslipidemias and atherosclerosis. <b>2021</b> , 116, 154461	21
294	Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: The CAVASIC study. <b>2021</b> , 316, 41-47	7
293	The association between lipoprotein (a) and carotid atherosclerosis in patients with type 2 diabetes without pre-existing cardiovascular disease: A cross-sectional study. <b>2021</b> , 171, 108622	7
292	Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers. <b>2021</b> , 15, 134-141	3
291	The potential value of Copeptin and Pentraxin3 for evaluating the severity of coronary stenosis in patients with coronary artery disease. <b>2021</b> , 87, 32-38	2
290	Lipoprotein(a) levels and risk of abdominal aortic aneurysm in the Women's Health Initiative. <b>2021</b> , 73, 1245-1252.e3	3
289	Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels. <b>2021</b> , 21, 255-265	2
288	FH through the retrospectroscope. <b>2021</b> , 62, 100036	4
287	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. <b>2021</b> , 10, 45	
286	Pediatric dyslipidemias: lipoprotein metabolism disorders in children. <b>2021</b> , 965-1022	
285	Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de los iPCSK9 en la práctica clínica. <b>2021</b> , 56, 39-48	4
284	Biomarkers. <b>2021</b> , 31-64	
283	Recent Updates of Lipoprotein(a) and Cardiovascular Disease. <b>2021</b> , 57, 36-43	3
282	Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a). <b>2021</b> , 28, 159-173	7

281	Impact of Dyslipidemia on Ischemic Stroke. <b>2021</b> , 23-41	
280	New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects. <b>2021</b> , 12, 603910	8
279	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <b>2021</b> , 319, 51-61	12
278	Lipoprotein(a) and Cardiovascular Outcomes after Revascularization of Carotid and Lower Limbs Arteries. <b>2021</b> , 11,	1
277	The Suggestive Effect of Apo A, Apo B, and Apo A/Apo B on Erectile Dysfunction. <b>2021</b> , 18, 448-456	0
276	Type 2 diabetes in South Asians compared to Europeans: Higher risk and earlier development of major cardiovascular events irrespective of the presence and degree of retinopathy. Results from The HinDu The Hague Diabetes Study. <b>2021</b> , 4, e00242	0
275	Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. <b>2021</b> , 77, 1576-1589	18
274	Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis. <b>2021</b> , 77, 397-407	11
273	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <b>2021</b> , 44, 1219-1227	9
272	Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines. <b>2021</b> , 33, 85-107	0
271	Meta-Analysis of Intensive Lipid-Lowering Therapy in Patients With Polyvascular Disease. <b>2021</b> , 10, e017948	6
270	Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. <b>2021</b> , 42, 2186-2196	15
269	Pleiotropic Effects of PCSK-9 Inhibitors. <b>2021</b> , 22,	5
268	Cardiovascular Risk Assessment in the Older Athlete. <b>2021</b> , 13, 622-629	0
267	Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines. <b>2021</b> , 33, 85-107	0
266	A Comparative Analysis of the Lipoprotein(a) and Low-Density Lipoprotein Proteomic Profiles Combining Mass Spectrometry and Mendelian Randomization. <b>2021</b> , 3, 450-459	5
265	Umbrella Review on Non-Statin Lipid-Lowering Therapy. <b>2021</b> , 26, 437-452	2
264	CARotid plaQUe StabilizatiOn and regression with evolocumab: Rationale and design of the CARUSO study. <b>2021</b> , 98, E115-E121	0

263	Coronary heart disease risk: Low-density lipoprotein and beyond. <b>2021</b> ,	6
262	PCSK9 Inhibition-A Tale of 2 Potential Treatment Opportunities-Reply. <b>2021</b> , 6, 481	
261	Inhibitors of Protein Convertase Subtilisin/Kexin 9 (PCSK9) and Acute Coronary Syndrome (ACS): The State-of-the-Art. <b>2021</b> , 10,	2
260	Lipoprotein(a): A Concealed Precursor of Increased Cardiovascular Risk? A Real-World Regional Lipid Clinic Experience. <b>2021</b> , 52, 397-404	2
259	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <b>2021</b> , 325, 99-109	22
258	Targeting IL-6 in patients at high cardiovascular risk. <b>2021</b> , 397, 2025-2027	2
257	A Critical Review of the Efficacy and Safety of Inclisiran. <b>2021</b> , 21, 629-642	5
256	Lipoprotein (a) is associated with poor long-term prognosis in patients aged 80 years and older with acute coronary syndrome. <b>2021</b> , 15, 466-476	2
255	Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic. <b>2021</b> , 44, 805-813	3
254	New Trends in Dyslipidemia Treatment. <b>2021</b> , 85, 759-768	4
253	The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: a Review. <b>2021</b> , 6, 247-258	5
252	Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. <b>2021</b> , 17, 528-542	14
251	Causal effects of plasma lipids on the risk of atrial fibrillation: A multivariable mendelian randomization study. <b>2021</b> , 31, 1569-1578	2
250	Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives. <b>2021</b> , 21, 815-834	4
249	Readability of Online Patient Education Materials Related to Lipoprotein(a): Systematic Review (Preprint).	
248	The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?. <b>2021</b> , 23, 40	6
247	Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy. <b>2021</b> , 23, 46	4
246	Novel RNAi-Based Therapies for Atherosclerosis. <b>2021</b> , 23, 45	2

245	The Association of Lipoprotein(a) and Circulating Monocyte Subsets with Severe Coronary Atherosclerosis. <b>2021</b> , 8,	4
244	Lipoprotein (a): Recent Updates on a Unique Lipoprotein. <b>2021</b> , 23, 41	3
243	Impact of Postprocedural High-Sensitivity C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk with ST-Segment Elevation Myocardial Infarction With Percutaneous Coronary Intervention. <b>2021</b> , 150, 8-14	0
242	Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity. <b>2021</b> , 1	3
241	Drugs for Prevention and Treatment of Aortic Stenosis: How Close Are We?. <b>2021</b> , 37, 1016-1026	2
240	The clinical role of combined serum C1q and hsCRP in predicting coronary artery disease. <b>2021</b> , 93, 50-58	0
239	Lipoprotein(a) and Cardiovascular Diseases. <b>2021</b> , 326, 352-353	7
238	The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All?. <b>2021</b> , 23, 97	3
237	The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors. <b>2021</b> ,	6
236	Lipoprotein (a): When to Measure and How to Treat?. <b>2021</b> , 23, 51	2
235	Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Therapy. <b>2021</b> , 9,	2
234	The Residual Risk Odyssey: From LDL to Lp(a). <b>2021</b> , 78, 434-436	4
233	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <b>2021</b> , 37, 1129-1150	62
232	Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. <b>2021</b> ,	1
231	Dyslipidemia in Patients with Kidney Disease. <b>2021</b> , 39, 353-363	1
230	Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China. <b>2021</b> , 101444	2
229	Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. <b>2021</b> , 78, e157-e174	7
228	Lipoprotein(a) Testing Patterns in a Large Health System. <b>2021</b> , 153, 43-50	0

227	Developmental trajectories of blockchain research and its major subfields. <b>2021</b> , 66, 101606	4
226	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <b>2021</b> , 78, 421-433	13
225	A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent. <b>2021</b> , 1	4
224	Substantially Elevated Atherosclerotic Risks in Japanese Severe Familial Hypercholesterolemia Defined by the International Atherosclerosis Society. <b>2021</b> , 1, 245-255	1
223	Lipoprotein(a) and subclinical coronary atherosclerosis in asymptomatic individuals. <b>2021</b> ,	1
222	Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies. <b>2021</b> , 17, 527-542	1
221	Lipoprotein(a) in Coronary Artery Bypass Graft Surgery Patients: An Underappreciated Opportunity to Optimise Cardiovascular Disease Prevention. <b>2021</b> , 30, e106-e107	
220	Predictors of Recurrent Ischemic Events in Patients With ST-Segment Elevation Myocardial Infarction. <b>2021</b> , 159, 44-51	3
219	Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases. <b>2021</b> , 9,	3
218	Update on proprotein convertase subtilisin/kexin type 9 inhibitors, lipoprotein(a) and cardiovascular risk. <b>2021</b> , 32, 324-327	1
217	Lipoprotein(a): Knowns, unknowns and uncertainties. <b>2021</b> , 173, 105812	12
216	Unravelling lipoprotein metabolism with stable isotopes: tracing the flow. <b>2021</b> , 124, 154887	2
215	Elevated lipoprotein(a) and risk of coronary heart disease according to different lipid profiles in the general Chinese community population: the CHCN-BTH study. <b>2021</b> , 9, 26	3
214	Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland. <b>2021</b> , 36, 370-378	1
213	Lipoprotein(a) and kidney diseases. <b>2021</b> , 25, 31-46	
212	[Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines]. <b>2021</b> , 38, 21-43	1
211	Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism. <b>2020</b> , 1276, 137-156	8
210	Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations. <b>2020</b> , 9, 275-292	7

209	Familial Hypercholesterolemia and Lipoprotein(a): Unraveling the Knot That Binds Them. <b>2020</b> , 75, 2694-2697	1
208	Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction. <b>2020</b> , 76, 395-401	5
207	PCSK9 inhibitors: Ratification of the role of LDL cholesterol in cardiovascular prevention. Towards a convergence of European and North American prevention guidelines?. <b>2020</b> , 220, 374-382	1
206	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <b>2020</b> , 41, 2313-2330	301
205	Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. <b>2020</b> ,	11
204	Lipoprotein (a) and diabetes mellitus: causes and consequences. <b>2021</b> , 28, 181-187	3
203	Novel behavioural approaches and implementation science for mitigating genetic risk of cardiovascular disease due to elevated lipoprotein(a). <b>2021</b> , 28, 174-180	3
202	Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?. <b>2020</b> , 31, 125-131	6
201	The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia. <b>2020</b> , 31, 305-312	7
200	Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions.	1
199	Serum Lipoprotein (a) levels in acute coronary syndrome; Comparison of younger and elderly patients with healthy controls. <b>2019</b> , 35, 1718-1723	2
198	Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities. <b>2020</b> , 23, 60-69	1
197	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. <b>2020</b> , 15, 1-9	21
196	Emerging Strategies for the Management of Atherogenic Dyslipidaemia. <b>2020</b> , 15, 1-3	5
195	Lp(a), ApoB and ApoB/ApoA1 Ratio as Potential Serum Markers for Predicting Early-Onset Acute Coronary Syndrome. <b>2019</b> , 6, 2754-2759	1
194	Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. <b>2021</b> , 22, 151-161	26
193	Therapeutic management of hyperlipoproteinemia (a). <b>2019</b> , 8, 212609	7
192	Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. <b>2021</b> ,	7



173	Lipoprotein (a): Principles from Bench to Bedside. <b>2021</b> , 363-381	
172	[New perspectives in the treatment of hypercholesterolaemia since the availability of PCSK9 inhibitors]. <b>2019</b> , 36, 213-220	
171	Current and Emerging Therapies for Atherosclerosis. <b>2020</b> , 71-88	
170	Online Patient Education Materials Related to Lipoprotein(a): Readability Assessment.. <b>2022</b> , 24, e31284	0
169	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl. <b>2020</b> , 15, e0240166	1
168	[Cardiovascular preventive recommendations. PAPPS 2020 update]. <b>2020</b> , 52 Suppl 2, 5-31	0
167	Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population. <b>2021</b> ,	3
166	Oxidized phospholipids and lipoprotein(a): An update. <b>2021</b> , e13710	1
165	Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a). <b>2021</b> ,	3
164	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. <b>2021</b> , 57, 1-99	
163	Association of PCSK9 Variants with the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy. <b>2021</b> , 101043	1
162	Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Soci�t� Francophone d'Atheroscl�se (NSFA). <b>2021</b> , 114, 828-847	1
161	Association of Lipoprotein(a)-Associated Mortality and the Estimated Glomerular Filtration Rate Level in Patients Undergoing Coronary Angiography: A 51,500 Cohort Study. <b>2021</b> , 8, 747120	0
160	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.. <b>2021</b> , 17, 1447-1547	8
159	Novel therapeutic targets and agents for pediatric dyslipidemia. <b>2021</b> , 12, 20420188211058323	2
158	Lipoprotein (a)-mediated vascular calcification: population-based and in vitro studies.. <b>2021</b> , 154960	2
157	Lipoprotein(a). <b>2021</b> , 201	4
156	Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know.. <b>2022</b> ,	4



155	Lipoprotein(a) and CT Angiography: Novel Insights Into High-Risk Plaque Progression.. <b>2022</b> , 79, 234-237	1
154	A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.. <b>2022</b> , 12,	3
153	ApoA and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) (Lipoprotein[a]) Levels by Modulation of ApoB Secretion.. <b>2022</b> , ATVBAHA121317335	6
152	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update.. <b>2021</b> , 343, 28-50	4
151	Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia.. <b>2022</b> , ,	3
150	PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentration.. <b>2022</b> ,	1
149	Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia.. <b>2022</b> , 1	4
148	A case of hyperlipoprotein(a)emia undergoing catheter interventions for coronary artery disease, aortic valve stenosis, and peripheral artery disease.. <b>2022</b> , 10, 2050313X221074464	
147	Perspective Chapter: Lipoprotein (a), Cardiac Amyloidosis, and Aortic Stenosis - Underestimated Associations.	
146	Therapeutic RNA-silencing oligonucleotides in metabolic diseases.. <b>2022</b> ,	4
145	Lipoprotein a: An emerging risk identifier and evolving clinical target. <b>2022</b> , 2, 1-3	
144	Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis.. <b>2022</b> , 12,	2
143	Lipoprotein(a) and Coronary Calcium: Clinical Management and Potential Design of Primary Prevention Trials.. <b>2022</b> , 79, 769-771	0
142	Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol.. <b>2022</b> , 79, 1035-1046	7
141	Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target.. <b>2022</b> ,	0
140	Impact of lipoprotein (a) on long-term outcome after percutaneous coronary intervention in the era of new generation drug-eluting stents.. <b>2022</b> ,	
139	Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India.. <b>2022</b> ,	0
138	Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part II. Clinical Characteristics.. <b>2022</b> , 13, 849267	1

137	Insight into the Evolving Role of PCSK9.. <b>2022</b> , 12,	3
136	Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.. <b>2022</b> ,	5
135	The relationship between lipoprotein(a) and cardiovascular events in acute coronary syndrome patients with and without chronic kidney disease.. <b>2022</b> ,	1
134	The Trajectory of Lipoprotein(a) During the Peri- and Early Postinfarction Period and the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition.. <b>2022</b> ,	0
133	Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.. <b>2021</b> , 12,	5
132	Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia. <b>2021</b> , 19, 498	0
131	Pharmacological interventions for the treatment of aortic root and heart valve disease. <b>2021</b> , 2021,	
130	Kardiovaskulärer Risikofaktor Dyslipidämie. <b>2022</b> , 1-14	
129	Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry.. <b>2022</b> ,	1
128	The correlation between lipoprotein(a) elevations and the risk of recurrent cardiovascular events in CAD patients with different LDL-C levels.. <b>2022</b> , 22, 171	0
127	Genetically proxied PCSK9 inhibition provides indication of lower prostate cancer risk: a Mendelian randomization study.	1
126	Suppression of PCSK9/NF-κB-dependent pathways by acetate ameliorates cardiac inflammation in a rat model of polycystic ovarian syndrome.. <b>2022</b> , 300, 120560	0
125	[Update on PCSK9 inhibition].. <b>2022</b> , 1	
124	The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy.. <b>2022</b> , 13, 491-520	0
123	Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.. <b>2022</b> ,	1
122	Smoking and Diabetes Attenuate Beneficial Effects of PCSK9 Inhibitors on Arterial Wall Properties in Patients with Very High Lipoprotein (a) Levels.	
121	Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis.. <b>2022</b> , 2022, 8729003	1
120	Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care.. <b>2022</b> , 13, 905941	1

119	Role of Lipoprotein(a) in Cardiovascular Disease: A Review of Clinical Practice. 1,	
118	Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial. <b>2022</b> , 9, 153	0
117	Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia.. <b>2022</b> , 11,	1
116	Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease. <b>2022</b> , 9,	1
115	Relationship between lipoprotein(a) and revascularization after percutaneous coronary intervention in type 2 diabetes mellitus patients with acute coronary syndrome.. <b>2022</b> , 1-30	
114	Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And Lipoprotein(a) reduction-DOSE Finding Study) Trial.. <b>2022</b> , 251, 61-61	1
113	Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.. <b>2022</b> ,	8
112	Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?. <b>2022</b> , 117, 28	1
111	Recent advances in demystifying the metabolism of lipoprotein(a). <b>2022</b> , 349, 82-91	8
110	Existing and emerging strategies to lower Lipoprotein(a). <b>2022</b> , 349, 110-122	9
109	Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome. <b>2022</b> , 20,	0
108	A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research. <b>2022</b> , 12,	
107	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients. <b>2022</b> , 11, 3247	0
106	Considerations for routinely testing for high Lp(a). <b>2022</b> , 33, 213-218	
105	Pre-clinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease.	0
104	Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. <b>2022</b> , 33, 147-159	0
103	Association of various lipid parameters with premature coronary artery disease in men. <b>2022</b> , 27, 5058	1
102	Relationship between Lipoprotein(a) and Dyslipidemia in the Elderly over 60 Years. <b>2022</b> , 54, 95-102	

101	New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.	0
100	Lipoprotein(a) When to Screen and How to Treat.	
99	Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. <b>2022</b> , 11, 3884	2
98	Dyslipidemia in Transplant Patients: Which Therapy?. <b>2022</b> , 11, 4080	0
97	The Inherited Hypercholesterolemias. <b>2022</b> ,	0
96	Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation. 9,	1
95	PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Volume 18, 555-566	3
94	Considerations for routinely testing for high lipoprotein(a). Publish Ahead of Print,	
93	Impact of lipoprotein(a) levels on primary patency after endovascular therapy for femoropopliteal lesions.	
92	Lipoprotein (a) in familial hypercholesterolaemia. Publish Ahead of Print,	
91	A Novel Biomarker Scoring System Alone or in Combination with the GRACE Score for the Prognostic Assessment in Non-ST-Elevation Myocardial Infarction. Volume 14, 911-923	
90	Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds. <b>2022</b> , 80, 934-946	3
89	Management of Dyslipidemia in Secondary Prevention of Cardiovascular Disease: The Gap between Theory and Practice. <b>2022</b> , 11, 4608	
88	Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study. <b>2022</b> ,	1
87	Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. <b>2022</b> , 7,	4
86	Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels. <b>2022</b> , 11,	1
85	Association between lipoprotein(a) and thromboembolism in patients with non-valvular atrial fibrillation: a cross-sectional study. <b>2022</b> , 21,	
84	Coronary Artery Calcium-Based Approach to Lipid Management.	

83	Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment.	
82	Smoking and diabetes attenuate beneficial effects of PCSK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels. <b>2022</b> , 50, 1-9	1
81	Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. <b>2022</b> , 146, 657-672	2
80	PCSK9 Inhibition: From Current Advances to Evolving Future. <b>2022</b> , 11, 2972	6
79	Lp(a). <b>2022</b> , 80, 1299-1301	0
78	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. <b>2022</b> ,	2
77	Contribution of Oxidative Stress (OS) in Calcific Aortic Valve Disease (CAVD): From Pathophysiology to Therapeutic Targets. <b>2022</b> , 11, 2663	1
76	Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.	17
75	Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions. 1-15	1
74	Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease.	0
73	Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke. <b>2022</b> ,	0
72	Acute impact of the early application of alirocumab on lipoprotein (a) and interleukin-6 in patients with unstable angina pectoris: a retrospective before-after study.	0
71	New Horizons: Revival of Lipoprotein (a) as a risk factor for cardiovascular disease.	0
70	Association of lipoprotein(a) with all-cause and cause-specific mortality: A prospective cohort study. <b>2022</b> ,	1
69	Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes.	3
68	Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention. <b>2022</b> ,	1
67	Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors. <b>2022</b> ,	0
66	Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies. <b>2022</b> , 11, 6040	1

65	Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study. 13,	0
64	Use of lipid-lowering therapy: the guidelines, the drugs or the patient? 2022, 24, 129-133	1
63	Recent Advances in Gene Therapy for Familial Hypercholesterolemia: An Update Review. 2022, 11, 6773	0
62	Review of recent clinical trials and their impact on the treatment of hypercholesterolemia. 2022,	2
61	Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease. 2022, 22,	0
60	Lipoprotein(a) variations between Chronic Coronary Syndrome and Acute Myocardial Infarction and their relation to the severity of coronary artery stenosis.	0
59	Lipoprotein(a) and Cardiovascular Disease in Chinese Population. 2022, 2, 653-665	0
58	Recent lipoprotein(a) trials. 2022, 33, 301-308	0
57	Recomendaciones preventivas cardiovasculares. Actualizaci3n PAPPs 2022. 2022, 54, 102444	0
56	Surf4, cargo trafficking, lipid metabolism, and therapeutic implications.	0
55	Coronary artery calcium scoring as a tool for risk stratification in patients with an elevated lipoprotein(a) level. 9,	0
54	Lipoprotein (a) Levels and Abdominal Aortic Aneurysm. A Systematic Review and Meta-analysis. 2022, 28, 3492-3499	2
53	Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy. 2022, 15, 1573	0
52	Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy. 2022, 19, 16899	0
51	Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option. 2023, 24, 170	0
50	Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle?. Publish Ahead of Print,	0
49	Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lp(a): An Update on New Therapies. 2022,	0
48	Association of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events. 2022, 5, e2245720	0

47	Lipoprotein (a) variability is associated with mean follow-up C-reactive protein in patients with coronary artery disease following percutaneous coronary intervention. 10, 12909-12919	○
46	Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol.	○
45	Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects. <b>2022,</b>	○
44	Research Progress of Lipoprotein a in Cardiovascular Disease. <b>2023, 13, 272-279</b>	○
43	Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. <b>2023, 20, e1003988</b>	○
42	The Value of Measuring Lipoprotein(a) in Children. <b>2023, 147, 32-34</b>	○
41	Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions. Volume 19, 31-41	○
40	Prognostic impact of lipoprotein(a) in patients undergoing percutaneous coronary intervention modified by low density lipoprotein cholesterol. <b>2023, 540, 117217</b>	○
39	Extreme lipoprotein(a) in clinical practice: A cross sectional study. <b>2023, 16, 200173</b>	○
38	Lp(a) - an overlooked risk factor. <b>2023,</b>	○
37	Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations. <b>2023,</b>	○
36	Effect of Early Use of Envolocumab on Cardiovascular Events in Patients with Extremely-High-Risk Atherosclerotic Cardiovascular Disease after Percutaneous Coronary Intervention. <b>2023, 13, 1346-1355</b>	○
35	Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Treatment for Repeated In-stent Restenosis in a Coronary Artery. <b>2023,</b>	○
34	Role of Proprotein Convertase Subtilisin Kexin Type 9 in Lipoprotein(a) Metabolism. <b>2023, 113-124</b>	○
33	Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results. <b>2023, 12,</b>	○
32	Association of Remnant-like Particle Cholesterol with Major Adverse Cardiovascular Events in Subjects with Different Levels of Proprotein Convertase Subtilisin/Kexin 9: A 9.5-year Follow-up Study in a Beijing Community Population. Publish Ahead of Print,	○
31	Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US study. <b>2023, 14, 100476</b>	○
30	Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. <b>2023, 28, 969</b>	1

- 29 Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses. **2023**, 367, 24-33 ○
- 28 Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis. ○
- 27 VLDL receptor gene therapy for reducing atherogenic lipoproteins. **2023**, 69, 101685 ○
- 26 Is it really a slam-dunk that reducing Lp(a) will decrease risk for cardiovascular events? Not so fast. **2023**, ○
- 25 Relationship between Lipoprotein a and Coronary Slow Flow Phenomenon. **2023**, 13, 2052-2058 ○
- 24 Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis. 14, ○
- 23 Lipoprotein(a): Its Association with Calcific Aortic Valve Stenosis, the Emerging RNA-Related Treatments and the Hope for a New Era in Treating Aortic Valve Calcification. **2023**, 10, 96 ○
- 22 Interaction between elevated lipoprotein(a) and LDL cholesterol on mortality risk in patients with coronary artery disease. ○
- 21 Measurement of Lipoprotein(a) in the Clinical Laboratory. **2023**, 281-295 ○
- 20 Unresolved Questions. **2023**, 425-435 ○
- 19 When Should We Measure Lipoprotein(a)? **2023**, 275-280 ○
- 18 Lipoprotein Apheresis for Reduction of Lipoprotein(a). **2023**, 377-407 ○
- 17 Therapy of Elevated Lipoprotein(a). **2023**, 347-357 ○
- 16 Lp(a) as a Cardiovascular Risk Factor. **2023**, 231-239 ○
- 15 Thrombosis, Inflammation, and Lipoprotein(a): Clinical Implications. **2023**, 189-206 ○
- 14 PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients. **2023**, ○
- 13 Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets. **2023**, 12, 2161 ○
- 12 Study on VLDLR Gene Therapy for Reducing Atherogenic Lipoprotein. **2023**, 13, 3424-3430 ○



- 11 Baseline Lipoprotein(a) Levels and Long-Term Cardiovascular Outcomes After Acute Myocardial Infarction. **2023**, 38, ○
- 10 Medical Therapy to Prevent or Slow Progression of Aortic Stenosis: Current Evidence and Future Directions. Publish Ahead of Print, ○
- 9 Effect of in-hospital evolocumab therapy on lipoprotein(a) in patients with acute myocardial infarction: a retrospective cohort study and a propensity score matching analysis. Publish Ahead of Print, ○
- 8 Classic endocrine disorders: implications for cardiovascular disease. **2023**, 233-270 ○
- 7 Computed tomographic angiography in coronary artery disease. **2023**, 18, e1307-e1327 ○
- 6 Lipoprotein(a): cardiovascular risk and emerging therapies. **2023**, 21, 259-268 ○
- 5 Guidelines on the Use of Therapeutic Apheresis in Clinical Practice [Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. **2023**, 38, 77-278 ○
- 4 Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. ○
- 3 Clinical Trial Design for Lipoprotein(a)-Lowering Therapies. **2023**, 81, 1633-1645 ○
- 2 Are we seeing the light at the end of the tunnel for high lipoprotein(a)? Lipoprotein(a). **2022**, 1, ○
- 1 Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels Potent Clinical Implications. **2023**, 16, 750 ○